Skip to content

Prevention of Relapse in Behavioral Disorders

Prevention of Relapse in Behavioral Disorders: Study Protocol of a Randomized Control Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07052175
Acronym
PreCare
Enrollment
150
Registered
2025-07-04
Start date
2026-04-01
Completion date
2026-12-01
Last updated
2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance-related Disorders

Keywords

Substance use disorders, relapse prevention, multidisciplinary treatment, digital health, monitoring

Brief summary

This study aims to validate the effectiveness of a digital tool for monitoring and early relapse detection in addiction treatment. It compares outcomes between a traditional multidisciplinary model and the same model enhanced by the technology. The research seeks to demonstrate the tool's added clinical value in improving long-term recovery outcomes.

Detailed description

The primary objective of this research project is to scientifically validate the effectiveness of a technological tool for monitoring and early detection of relapse in addiction treatment. The study will focus on comparing two approaches: the traditional comprehensive multidisciplinary treatment model and the same model enhanced by the integration of a digital technology. The comprehensive model addresses the biological, psychological, and social dimensions of substance use disorders through a structured sequence of phases: initial assessment, detoxification, withdrawal management, rehabilitation, social reintegration, and follow-up care. The core innovation of this study lies in the implementation of a digital application specifically designed to monitor patients' clinical status, detect early warning signs of relapse, and deliver timely, personalized interventions. A longitudinal quasi-experimental study will be conducted with a sample of 150 individuals diagnosed with substance use disorders (including alcohol, cocaine, and other stimulants). Validated assessment instruments will be used to evaluate clinical progress, comparing outcomes between patients receiving standard treatment and those receiving the same treatment augmented by the digital tool. Key outcome variables include reduction in withdrawal symptoms, decrease in craving, improvement in emotional well-being and psychosocial functioning, relapse rates, and patient satisfaction. In addition, the feasibility, acceptability, and clinical utility of the technological tool in therapeutic follow-up will be assessed. The study is expected to provide empirical evidence on the added value of the digital tool in addiction treatment, with the aim of optimizing existing clinical protocols and enhancing the long-term effectiveness of intervention strategies.

Interventions

BEHAVIORALStandard Multidisciplinary Treatment

Comprehensive intervention including structured phases: initial assessment, detoxification, withdrawal management, psychological and psychiatric therapy, rehabilitation, and follow-up care. Delivered by a multidisciplinary team according to established clinical protocols.

BEHAVIORALDigital Monitoring Tool

In addition to standard care, participants will use a mobile application that monitors clinical indicators, detects early signs of relapse risk, and provides personalized alerts and intervention prompts. The tool is designed to support both patients and clinicians in decision-making and therapeutic follow-up.

Sponsors

Clínica Nuestra Señora de la Paz
Lead SponsorOTHER
Universidad Carlos III de Madrid
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Randomized Control Trial, efficacy study

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Understand spoken and written Spanish. * Signing the informed consent. * Own a smartphone with internet access and an iOS or Android operating system.

Exclusion criteria

* Institutionalized or incarcerated patients, or those anticipating imminent incarceration, without regular access to mobile phone use. * Refusal to install the mobile application. * Inability to understand and sign the informed consent form for any reason.

Design outcomes

Primary

MeasureTime frameDescription
Biological Verification of Substance Use Relapse via Toxicological Testing: UrinalysisThroughout the intervention and follow-up phases (baseline to 12 months)To objectively identify episodes of relapse (e.g., alcohol or other substance use) during treatment, periodic toxicological screenings will be performed as part of the therapeutic monitoring process. These screenings are conducted by clinical personnel and include urinalysis: detection of recent use of psychoactive substances through urine samples, providing an objective measure of treatment adherence.
Biological Verification of Substance Use Relapse via Toxicological Testing: Breath Alcohol TestingThroughout the intervention and follow-up phases (baseline to 12 months)To objectively identify episodes of alcohol relapse during treatment, periodic toxicological screenings will be conducted as part of the therapeutic monitoring process. These screenings will be carried out by clinical staff and will include Breath Alcohol Testing: measurement of breath alcohol concentration using spirometry-based devices to detect recent alcohol consumption.

Secondary

MeasureTime frameDescription
WHOQOL-BREFBaseline, post-treatment (3 months), and follow-up (6 and 12 months)A 26-item instrument assessing perceived quality of life across four domains: physical health, psychological well-being, social relationships, and environmental context. Items are rated on a 5-point Likert scale, and domain scores are transformed to a 0-100 scale. Demonstrates good internal consistency, with Cronbach's alpha ranging from 0.69 (physical) to 0.90 (spirituality/religion/personal beliefs).
Purpose in Life Test - Short Form (PIL-10)Baseline, post-treatment (3 months), and follow-up (6 and 12 months)A 10-item self-report scale assessing life purpose and personal meaning, adapted from the original PIL (Crumbaugh \& Maholick, 1969). Responses are rated on a 7-point Likert scale, with total scores ranging from 10 to 70. Higher scores reflect greater perceived purpose. The scale includes two dimensions: (a) life satisfaction and meaning, and (b) goals and direction. Shows good psychometric properties (α = .85 overall; .84 for life satisfaction and .69 for goals and purpose).
Patient Health Questionnaire-9 (PHQ-9)Baseline, post-treatment (3 months), and follow-up (6 and 12 months)A 9-item self-report tool assessing depressive symptom severity over the past two weeks, based on DSM-IV criteria. Each item is scored from 0 (not at all) to 3 (nearly every day), yielding a total score of 0-27. A cut-off score of 10 yields sensitivity of 0.78 and specificity of 0.87. Spanish versions show excellent reliability (α = 0.78-0.90), with current data showing α = .93.
Beliefs About Substance Use and Craving Beliefs QuestionnaireBaseline, post-treatment (3 months), and follow-up (6 and 12 months)25 items self-report questionnaire designed to assess maladaptive beliefs related to substance use and beliefs about substance craving. Each item is rated on a 5-point Likert scale ranging from "totally disagree" to "totally agree". Higher total scores reflect stronger dysfunctional beliefs associated with substance use (e.g., perceived benefits or inevitability of use). The instrument shows excellent internal consistency (Cronbach's alpha = 0.87).

Countries

Spain

Contacts

CONTACTRafael Salom Borrás, PhD
rafael.salom@sjd.es+34 914 15 60 00
CONTACTÁlvaro Pico Rada, Psychiatrist and Medical Direc
alvaro.pico@sjd.es+34 914 15 60 00
PRINCIPAL_INVESTIGATORJuan Jesús Muñoz García, PhD

Centro San Juan de Dios de Ciempozuelos

PRINCIPAL_INVESTIGATORAntonio Artés, PhD

Department of Signal Theory at Universidad Carlos III

PRINCIPAL_INVESTIGATORApolo Zepeda Avilés, Medical Director

Hospital San Juan de Dios de Gipuzkoa

PRINCIPAL_INVESTIGATOREnrique Bermúdez Navas, Psychiatrist

Centro Asistencial San Juan de Dios Palencia

PRINCIPAL_INVESTIGATORPlacidia Franco Suárez-Bárcena, Technical Director

Centro Asistencial San Juan de Dios Palencia

PRINCIPAL_INVESTIGATORRafael Salom Borrás, PhD

Clínica Nuestra Señora de la Paz, Orden Hospitalaria San Juan de Dios, Madrid, Spain

PRINCIPAL_INVESTIGATORÁlvaro Pico Rada, Medical Director

Clínica Nuestra Señora de la Paz, Orden Hospitalaria San Juan de Dios, Madrid, Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026